After a healthy correction of 10% Nasdaq Biotech returns to the uptrend channel, before delivery of quarterly results
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
